| 26.6 0.24 (0.91%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.61 | 1-year : | 38.09 |
| Resists | First : | 27.92 | Second : | 32.61 |
| Pivot price | 26.1  |
|||
| Supports | First : | 25.43 | Second : | 23.89 |
| MAs | MA(5) : | 26.32 |
MA(20) : | 26.17 |
| MA(100) : | 23.48 |
MA(250) : | 19.16 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 62 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 27.92 | Low : | 12.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMVT ] has closed below upper band by 34.2%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.81 - 26.91 | 26.91 - 27 |
| Low: | 25.47 - 25.6 | 25.6 - 25.71 |
| Close: | 26.37 - 26.59 | 26.59 - 26.77 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Tue, 17 Feb 2026
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Tue, 17 Feb 2026
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tue, 17 Feb 2026
10:48 ETSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - Longbridge
Mon, 09 Feb 2026
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat - MarketBeat
Sat, 07 Feb 2026
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript - Insider Monkey
Mon, 02 Feb 2026
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 201 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 57.2 (%) |
| Held by Institutions | 48.8 (%) |
| Shares Short | 16,930 (K) |
| Shares Short P.Month | 14,960 (K) |
| EPS | -2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -55.5 % |
| Return on Equity (ttm) | -96 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -431 (M) |
| Levered Free Cash Flow | -270 (M) |
| PE Ratio | -9.61 |
| PEG Ratio | 0 |
| Price to Book value | 8.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|